These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31199450)

  • 1. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
    Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
    JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
    Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
    Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
    Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
    Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Perez JR; Agarwal N; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):e573-e582. PubMed ID: 28139444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database.
    Vaishampayan U; Vankayala H; Vigneau FD; Quarshie W; Dickow B; Chalasani S; Schwartz K
    Clin Genitourin Cancer; 2014 Apr; 12(2):124-9. PubMed ID: 24225251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain RK; Chahoud J; Spiess PE; Sexton W; Gilbert SM; Manley BJ
    JAMA Netw Open; 2021 May; 4(5):e2111329. PubMed ID: 34032854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
    Conti SL; Thomas IC; Hagedorn JC; Chung BI; Chertow GM; Wagner TH; Brooks JD; Srinivas S; Leppert JT
    Int J Cancer; 2014 May; 134(9):2245-52. PubMed ID: 24135850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.
    Sierra PS; Cordeiro MD; Albuquerque EV; Bastos DA; Bonadio RC; Sarkis AS; Cavalcante A; Pontes J; Coelho RF; Nahas WC
    Clin Genitourin Cancer; 2020 Apr; 18(2):e134-e144. PubMed ID: 31980410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.
    Aspinall SL; Zhao X; Geraci MC; Good CB; Cunningham FE; Heron BB; Becker D; Lee S; Prasad V;
    Cancer Med; 2019 Nov; 8(15):6651-6661. PubMed ID: 31536684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
    Goel S; Negassa A; Acuna-Villaorduna A
    JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma.
    Chakiryan NH; Acevedo AM; Garzotto MA; Chen Y; Liu JJ; Isharwal S; Amling CL; Kopp RP
    Urol Oncol; 2020 Jun; 38(6):604.e1-604.e7. PubMed ID: 32241693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
    Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
    J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.